EDITAS MEDICINE, INC. (EDIT) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 153.58M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 153.58M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 153.58M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 153.58M | (m) | (m) |
| 2026-03-31 | 97.91M | (m) | (m) |
| 2025-12-31 | 97.87M | (m) | (m) |
| 2025-09-30 | 97.62M | (m) | (m) |
| 2025-06-30 | 89.92M | (m) | (m) |
| 2025-03-31 | 83.71M | (m) | (m) |
| 2024-12-31 | 82.98M | (m) | (m) |
| 2024-09-30 | 82.55M | (m) | (m) |
| 2024-06-30 | 82.48M | (m) | (m) |
| 2024-03-31 | 82.24M | (m) | (m) |
| 2023-09-30 | 81.67M | (m) | (m) |
| 2023-06-30 | 81.63M | (m) | (m) |
| 2023-03-31 | 69.00M | (m) | (m) |
| 2022-09-30 | 68.76M | (m) | (m) |
| 2022-06-30 | 68.74M | (m) | (m) |
| 2022-03-31 | 68.64M | (m) | (m) |
| 2021-12-31 | 68.52M | (m) | (m) |
| 2021-09-30 | 68.40M | (m) | (m) |
| 2021-06-30 | 68.26M | (m) | (m) |
| 2021-03-31 | 67.83M | (m) | (m) |
| 2020-12-31 | 67.36M | (m) | (m) |
| 2020-09-30 | 62.33M | (m) | (m) |
| 2020-06-30 | 62.27M | (m) | (m) |
| 2020-03-31 | 55.00M | (m) | (m) |
| 2019-12-31 | 54.88M | (m) | (m) |
| 2019-09-30 | 51.30M | (m) | (m) |
| 2019-06-30 | 49.52M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |